AACR 2023 | SWOG S1512: pembrolizumab in desmoplastic melanoma

Kari Kendra, MD, PhD, The Ohio State University, Columbus, OH, presents findings from the Phase II SWOG S1512 trial (NCT02775851) of pembrolizumab in patients with desmoplastic melanoma, a form of melanoma commonly found in areas of high sun exposure such as the head and neck. Pembrolizumab was found to produce clinically meaningful, durable responses in the first 9 months of treatment. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.